CDK6/PIM1-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

CDK6/PIM1-IN-1 

CDK6/PIM1-IN-1 是一种有效且平衡的双重 CDK6/PIM1 抑制剂,IC50 分别为 39 nM 和 88 nM。CDK6/PIM1-IN-1 抑制 CDK4 (IC50=3.6 nM)。CDK6/PIM1-IN-1 可显著抑制急性髓系白血病 (AML) 细胞增殖,将细胞周期阻滞在 G1 期,并促进细胞凋亡。CDK6/PIM1-IN-1 具有抗AML活性。

CDK6/PIM1-IN-1

CDK6/PIM1-IN-1 Chemical Structure

CAS No. : 2677026-14-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK6/PIM1-IN-1 is a potent and balanced dual CDK6/PIM1 inhibitor with IC50 values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC50=3.6 nM). CDK6/PIM1-IN-1 significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity[1].

IC50 & Target[1]

CDK6/cyclinD1

39 nM (IC50)

PIM1

88 nM (IC50)

CDK1/cyclinB

>10 μM (IC50)

CDK2/cyclinA

2.274 μM (IC50)

CDK3/Cyclin E

>10 μM (IC50)

Cdk4/cyclin D1

3.6 nM (IC50)

Cdk5/p25

>10 μM (IC50)

CDK7/Cyclin H/MNAT1

393 nM (IC50)

CDK9/cyclinT1

440 nM (IC50)

CDK12/Cyclin K

>10 μM (IC50)

CDK13/Cyclin K

>10 μM (IC50)

PIM2

>10 μM (IC50)

PIM3

92 nM (IC50)

体外研究
(In Vitro)

CDK6/PIM1-IN-1 (compound 51) exhibits more than 10 times selectivity over CDK1 (IC50>10 μM), CDK2 (IC50=2.274 μM), CDK3 (IC50>10 μM), CDK5 (IC50>10 μM), CDK7 (IC50=393 nM), CDK9 (IC50=440 nM), CDK12 (IC50>10 μM), and CDK13 (IC50>10 μM). CDK6/PIM1-IN-1 shows inhibitory activity against PIM2 (IC50>10 μM) and PIM3 (IC50=92 nM)[1].
CDK6/PIM1-IN-1 inhibits proliferation in AML cells (K562 cell,GI50=1.026 μM; HL-60 cell,GI50=1.069 μM; MOLM13 cell, GI50=1.362 μM)[1].
CDK6/PIM1-IN-1 (0.5, 1, 1.5 μM) causes a G1 arrest in a dose-dependent manner in K562 and HL-60 cell lines[1].
CDK6/PIM1-IN-1 (1, 2, 4 μM) promotes the apoptosis of K562 and HL-60 cell lines in a dose-dependent manner[1].
CDK6/PIM1-IN-1 (0.5, 1, 1.5 μM; for 24 h) reduces p-retinoblastoma (RB) and p-BAD levels in a concentration-dependent manner. CDK6/PIM1-IN-1 decreases the PIM1 level[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

CDK6/PIM1-IN-1 (compound 51; orally; 60, 90 mg/kg/day; 17 days) displays more potent antitumor activity in BALB/c mice with K562 cell lines[1].
CDK6/PIM1-IN-1 (iv; 5 mg/kg) has the t1/2, MRT0-∞, and AUC0-∞ values of 9.78 h, 14.61 h, and 1153.74 h·ng/mL, respectively in Sprague–Dawley (SD) rats[1].
CDK6/PIM1-IN-1 (po; 5 mg/kg) has the t1/2, Tmax, Cmax, and AUC0-∞ of 15.81 h, 11 h, 152.31 ng/mL, and 5152.92 h·ng/mL, respectively in SD rats[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

473.55

Formula

C25H28FN9

CAS 号

2677026-14-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Kai Yuan, et al. Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2022 Jan 13;65(1):857-875.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务